The murine anti-VEGF antibody used in the preclinical tumor models was humanized [10] and the recombinant antibody later known as bevacizumab was granted Federal Drug Administration (FDA) approval in 2004 for metastatic colorectal cancer [5]. The gene discussed is VEGFA; the disease is metastatic colorectal cancer.